Antimicrobial Resistance and Hospital Acquired Infections Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain.
Drug Discov Today. 2019 May;24(5):1132-1138. doi: 10.1016/j.drudis.2019.03.002. Epub 2019 Mar 8.
Widespread antibiotic resistance threatens the continued efficacy of antimicrobial therapy based on small-molecule antibiotics. Infections caused by multidrug-resistant Gram-negative bacteria are particularly worrisome owing to the lack of antimicrobials retaining sufficient activity against these microorganisms. Despite the explosion in monoclonal antibody therapies that have been developed for oncologic and rheumatic indications, only three antibacterial monoclonal antibodies have been approved for clinical use. In the present review, the therapeutic potential of this drug class for treating multidrug-resistant infections is discussed, and considerations for the development of antibacterial monoclonal antibodies are presented. Finally, the state of development of monoclonal antibody therapies for some of the most problematic multidrug-resistant Gram-negative infections is summarized.
广泛的抗生素耐药性威胁着基于小分子抗生素的抗菌治疗的持续疗效。由于缺乏对这些微生物仍具有足够活性的抗菌药物，由耐多药革兰氏阴性菌引起的感染尤其令人担忧。尽管已经开发出用于肿瘤学和风湿性疾病适应证的单克隆抗体治疗方法呈爆炸式增长，但仅有 3 种抗细菌单克隆抗体被批准用于临床应用。在本综述中，讨论了该药物类别治疗耐多药感染的治疗潜力，并提出了开发抗细菌单克隆抗体的注意事项。最后，总结了一些最棘手的耐多药革兰氏阴性菌感染的单克隆抗体治疗方法的开发状况。
